Control Cohort CTRL COH

Hospices Civils de Lyon1 个研究点分布在 1 个国家目标入组 350 人2023年8月8日

适应症Parkinson's Disease; Amyotrophic Lateral Sclerosis; Glioblastoma; Cancer Without Neurological Disease; Rheumatoid Polyarthritis

干预措施Collection of biological sample (blood and/or CSF)

概览

阶段: 不适用
干预措施: Collection of biological sample (blood and/or CSF)
疾病 / 适应症: Parkinson's Disease; Amyotrophic Lateral Sclerosis; Glioblastoma; Cancer Without Neurological Disease; Rheumatoid Polyarthritis
发起方: Hospices Civils de Lyon
入组人数: 350
试验地点: 1
主要终点: Samples (blood dry and EDTA tube and optional cerebro-spinal-fluid)
状态: 招募中
最后更新: 3个月前

概览研究者入排标准研究组 & 干预措施结局指标研究点相似试验

概览

简要总结

Autoimmune encephalitis (AE) and paraneoplastic neurological syndromes (PNS) are rare disease that could be difficult to diagnose. So it necessary to obtain numerous sample from different disease to develop more specific diagnosis kit It could be possible through the characterisation of new genetic biomarkers.

注册库

clinicaltrials.gov

开始日期

2023年8月8日

结束日期

2028年8月8日

最后更新

3个月前

研究类型

Interventional

研究设计

Single Group

性别

All

研究者

发起方

Hospices Civils de Lyon

责任方

Sponsor

入排标准

入选标准

•patient with consent
•patient with following disease: Parkinson's disease, Amyotrophic lateral sclerosis, Glioblastoma, cancer without neurological disease (pulmonary cancer, breast cancer, ovarian cancer, melanoma, thymoma), rheumatoid arthritis.

排除标准

•refusal consent
•patient with neurological disorder compatible with paraneoplastic neurological syndrome or auto-immune encephalitis
•patient under guardianship

研究组 & 干预措施

Control cohort

Patient with following disease: Parkinson's disease, Amyotrophic lateral sclerosis, Glioblastoma, cancer without neurological disease (pulmonary cancer, breast cancer, ovarian cancer, melanoma, thymoma), rheumatoid arthritis.

干预措施: Collection of biological sample (blood and/or CSF)